What it's for (Indications)
- Treatment of edema including cardiac edema, pulmonary edema (fluid in lungs), cerebral edema (water accumulation in brain), and peripheral edema (swelling of lower limbs).
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage regimen for furosemide and amiloride combination therapy, such as Duride, is highly individualized and determined by the patient's specific clinical condition, including the severity of fluid retention (edema), degree of hypertension, and existing renal function. A common starting dose for adult patients, particularly in cases of edema or hypertension requiring combined diuretic action, is one tablet containing Furosemide 40 mg and Amiloride 5 mg, administered orally once daily. It is generally recommended to take the medication in the morning to minimize the disruption of sleep due to increased nocturia. Dosage adjustments should be made incrementally, based on the patient's clinical response, which includes the resolution of edema, effective blood pressure control, and crucially, close monitoring of serum electrolyte levels (especially potassium, sodium, and magnesium) and renal function parameters (e.g., serum creatinine, blood urea nitrogen, estimated glomerular filtration rate). The goal of therapy is to achieve the desired therapeutic effect with the lowest effective dose, while maintaining electrolyte balance and minimizing the risk of adverse events. In certain severe or resistant cases, higher doses or a twice-daily regimen might be considered, but this must be done under strict medical supervision with intensified monitoring. Patients must be advised against self-adjusting their dose and should maintain regular follow-up appointments with their healthcare provider to assess efficacy and safety. |
Safety & Warnings
Common Side Effects
- Patients may experience electrolytes balance disturbances, allergic reactions, or dehydration.
- Consult your doctor if you experience any of these symptoms.
Serious Warnings
- Black Box Warning: WARNING: HYPERKALEMIA. The amiloride component of this combination product can cause hyperkalemia, which may be severe, life-threatening, and potentially fatal. This risk is significantly increased in patients with renal impairment (including conditions such as diabetic nephropathy, severe chronic kidney disease, or in cases of acute renal failure where glomerular filtration is compromised), diabetes mellitus, or in elderly patients who may have reduced renal function. Concomitant use with other potassium-sparing agents (e.g., spironolactone, eplerenone, triamterene), potassium supplements, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or aldosterone antagonists significantly elevates the risk of developing hyperkalemia. Serum potassium levels must be monitored carefully and regularly, especially at treatment initiation, during dosage adjustments, and in all patients at high risk. If hyperkalemia develops (serum potassium >5.5 mEq/L), the combination product should be immediately discontinued, and appropriate medical management initiated promptly to prevent cardiac arrhythmias or other serious sequelae. This serious adverse effect necessitates vigilant patient selection, thorough pre-treatment assessment, and ongoing laboratory surveillance to mitigate risk and ensure patient safety.
- Pregnancy: Not recommended during pregnancy.
- Consult your doctor for more information.
- Lactation: Not recommended during nursing.
- Consult your doctor for more information.
- Driving: This medicine might cause dizziness and blurred vision; avoid driving until you know how it affects you.
- Liver & Kidney: Caution is advised for patients with liver or kidney conditions.
- Consult your doctor for more information.
- Alcohol: Avoid alcohol consumption when using this medicine as it may further lower your blood pressure and increase side effects.
- Precautions: Before using this medicine, inform your doctor about your complete medical history, especially about kidney or liver diseases, gout, lupus, diabetes, difficulty urinating, and prostate problems.
- Inform your doctor about all your current medicines.
- Do not discontinue this medicine without informing your doctor.
- Inform your doctor if you are having surgery.
How it Works (Mechanism of Action)
The therapeutic efficacy of the furosemide and amiloride combination, exemplified by Duride, stems from the synergistic actions of its two distinct diuretic components on different segments of the renal tubule. Furosemide, a potent loop diuretic, exerts its primary effect in the thick ascending limb of the loop of Henle. Here, it reversibly inhibits the Na+-K+-2Cl− cotransporter (NKCC2) located on the luminal membrane of the tubular epithelial cells. By blocking this crucial transporter, furosemide prevents the reabsorption of sodium, potassium, and chloride ions from the tubular fluid back into the bloodstream. This profound inhibition leads to a significant increase in the excretion of these electrolytes, along with a substantial volume of water due to the resulting osmotic gradient, causing powerful diuresis, natriuresis, and kaliuresis. Concurrently, amiloride is a potassium-sparing diuretic that acts primarily in the late distal tubule and cortical collecting duct. Its mechanism involves directly blocking the epithelial sodium channels (ENaC) on the luminal membrane of the principal cells. By inhibiting ENaC, amiloride reduces the reabsorption of sodium ions. This decrease in sodium reabsorption subsequently diminishes the transepithelial electrical potential difference, which is a major driving force for potassium and hydrogen ion secretion. Consequently, amiloride reduces the excretion of potassium ions, promoting their retention, and thus effectively counteracts the hypokalemic tendency induced by furosemide. The combination provides robust diuresis and antihypertensive effects, while the inclusion of amiloride mitigates the common adverse effect of hypokalemia associated with potent loop diuretics, thereby offering a more balanced electrolyte profile.